|
AU2008207455A1
|
|
Novel compositions and methods in cancer associated with altered expression of TBX21
|
|
AU2008202138A1
|
|
Novel compositions and methods in cancer associated with altered expression of MCM3AP
|
|
AU2007240202A1
|
|
Novel compositions and methods for cancer
|
|
US2007212351A1
|
|
Therapeutic targets in cancer
|
|
CA2572509A1
|
|
Novel compositions and methods in cancer
|
|
AU2004276831A1
|
|
Fractal-forming alkylketene dimers for integral membrane protein crystal growth
|
|
CA2539664A1
|
|
Rho antibody and tag to purify cell surface proteins
|
|
US2009215711A1
|
|
Novel compositions and methods in cancer
|
|
US2006194210A1
|
|
Therapeutic targets in cancer
|
|
AU2004213432A1
|
|
Novel therapeutic targets in cancer
|
|
EP2058408A2
|
|
Therapeutic GPCR targets in cancer
|
|
AU2003299645A1
|
|
Novel compositions and methods in cancer
|
|
AU2003299646A1
|
|
Novel therapeutic targets in cancer
|
|
US7767387B2
|
|
Therapeutic targets in cancer
|
|
EP1501855A2
|
|
Novel compositions and methods in cancer
|
|
EP1490688A1
|
|
Novel compositions and methods in cancer associated with altered expression of prdm 11
|
|
AU2003230669A1
|
|
Novel compositions and methods in cancer associated with altered expression of TBX21
|
|
EP1490690A2
|
|
Novel compositions and methods in cancer associated with altered expression of mcm3ap
|
|
WO03071933A2
|
|
Novel compositions and methods for cancer
|
|
US2004197778A1
|
|
Novel compositions and methods in cancer
|
